The clinical benefit for patients with diverse types of metastatic cancers that has been observed upon blockade of the interaction between PD-1 and PD-L1 has highlighted the importance of this inhibitory axis in the suppression of tumour-specific T-cell responses 1-9 . Notwithstanding the key role of PD-L1 expression by cells within the tumour micro-environment, our understanding of the regulation of the PD-L1 protein is limited 10-15 . Here we identify, using a haploid genetic screen, CMTM6, a type-3 transmembrane protein of previously unknown function, as a regulator of the PD-L1 protein. Interference with CMTM6 expression results in impaired PD-L1 protein expression in all human tumour cell types tested and in primary human dendritic cells. Furthermore, through both a haploid genetic modifier screen in CMTM6-deficient cells and genetic complementation experiments, we demonstrate that this function is shared by its closest family member, CMTM4, but not by any of the other CMTM members tested. Notably, CMTM6 increases the PD-L1 protein pool without affecting PD-L1 (also known as CD274) transcription levels. Rather, we demonstrate that CMTM6 is present at the cell surface, associates with the PD-L1 protein, reduces its ubiquitination and increases PD-L1 protein half-life.
PD-L1 low cells. Specifically, whereas PD-L1 low cells showed the expected enrichment of integrations towards the 5′ end of the gene, a strong enrichment of integrations in intron 5 and 6 was observed in PD-L1 high cells (Extended Data Fig. 1b ), fully consistent with the recently described negative regulatory role of the PD-L1 3′ untranslated region (UTR) 11 (Extended Data Fig. 1c ).
In addition to the above hits, we identified CMTM6 (CKLF (chemokine-like factor)-like MARVEL transmembrane domain containing family member 6) as one of the most significant hits within PD-L1 low cells. CMTM6 was not observed in a similar screen for regulators of IRF1 protein levels 20 , suggesting that its role was independent of the IFNγR pathway. CMTM6 is a ubiquitously expressed transmembrane protein that belongs to a family of eight MARVELdomain-containing proteins 22 for which no clear function has been described. Transcriptome analysis of tumour samples in The Cancer Genome Atlas (TCGA) showed CMTM6 expression in all of the analysed samples distributed across 30 cancer types, and showed that RNA expression levels of CMTM6 and CD274 are weakly correlated in the majority of tumour types (Extended Data Fig. 2 ). Short hairpin RNA (shRNA)-mediated knockdown of CMTM6 in HAP1 cells reduced IFNγ-induced PD-L1 expression approximately twofold compared to control (Fig. 1b, c) . To assess whether CMTM6 also influences PD-L1 cell surface levels beyond the HAP1 system, we examined the effect of CMTM6 knockdown in a series of tumour lines. In A375 melanoma cells, which only show detectable PD-L1 expression after IFNγ exposure, CMTM6 knockdown prevented IFNγ-induced PD-L1 expression to a large extent ( Fig. 2a -c, reduction up to 11-fold). CMTM6deficient A375 clones generated with CRISPR-Cas9 likewise showed reduced cell surface and overall PD-L1 protein levels, whereas lentiviral reconstitution of CMTM6 reverted this phenotype (Fig. 2d, e ). In the 8505C thyroid cancer cell line, which has a high basal level of PD-L1 expression, both steady state and IFNγ-induced PD-L1 cell surface and total protein levels were substantially reduced by CMTM6 knockdown (Fig. 2f , g, up to seven-and fivefold, respectively). In total, we assessed the effect of CMTM6 knockdown in 12 human tumour lines, representing melanoma (Fig. 2a-c and Extended Data Fig. 3a-d ), thyroid cancer ( Fig. 2f, g) , colorectal cancer (Extended Data Fig. 3e , f, i, k), lung cancer (Extended Data Fig. 3l , n-p) and chronic myeloid leukaemia (Fig. 1b, c) . In addition, we also tested the effect of CMTM6 knockdown in three short-term cultures of melanoma xenografts (Extended Data Fig. 3q ). In these different cell systems, we consistently observed decreased expression of PD-L1 (between 2-and 11-fold) upon knockdown of CMTM6. Reduced PD-L1 cell surface levels were likewise observed when cells were stained with recombinant PD-1-Fc protein (Extended Data Fig. 3h , j, m). PD-L1 can be expressed by both cancer cells and infiltrating immune cells, and PD-L1 expression on immune cells may contribute to T-cell inhibition 16, 17 . To assess whether CMTM6 also influences PD-L1 levels in primary human dendritic cells, we generated dendritic cells from human bone marrow progenitors 23 . Comparison of lipopolysaccharide (LPS)-induced PD-L1 expression in control and CMTM6-knockdown dendritic cells showed that partial knockdown of CMTM6 resulted in a partial reduction of PD-L1 cell-surface levels (Fig. 2h, i) .
The above data establish CMTM6 as a modulator of PD-L1 protein levels. Whereas in some tumour lines, the effect of CMTM6 knockdown is strong (for example, A375, 8505C), in others it is moderate (for example, HAP1), suggesting the possible existence of (an) additional regulator(s). We therefore generated CMTM6-knockout HAP1 cells and performed a modifier screen, with the aim of identifying genetic factors that selectively regulate PD-L1 in the absence of CMTM6. Consistent with the primary screen, genes mediating IFNγR signalling were prominent hits. As expected, in this setting, integrations within the CMTM6 locus were no longer enriched within the PD-L1 low cell population ( Fig. 3a and Supplementary Table 2 ). In CMTM6-deficient HAP1 cells, CMTM4, another member of the CMTM family with 55% homology to CMTM6, was identified as a positive regulator of PD-L1 expression ( Fig. 3a) . Notably, although CMTM4 is a highly significant hit in CMTM6-deficient HAP1 cells (36.7-fold, false discovery rate (FDR)-corrected P ≤ 10 −314 ), it is not in CMTM6-proficient HAP1 cells (0.9-fold, FDR-corrected P = 0.94789), suggesting that in this system, CMTM4 functions as a back-up regulator of PD-L1 expression.
To validate these data, we transduced H2030 cells, in which CMTM6 depletion modestly suppresses PD-L1 expression and CMTM4 is highly expressed, with shRNAs against CMTM4 and CMTM6, either separately or in combination. In these cells, silencing of CMTM6 led to repression of IFNγ-induced PD-L1 expression that was further x axis indicates the number of disruptive insertions per gene; y axis shows the frequency of independent insertions in the PD-L1 high channel over the frequency of insertions in the PD-L1 low channel for each gene.
Light-blue and orange dots indicate genes with significant enrichment of insertions (FDR-corrected P < 10 −6 ) 27 c, Western blot analysis of CMTM6 and PD-L1 expression in control or independent CMTM6-knockdown A375 melanoma cells with or without IFNγ exposure. d, e, Flow cytometry (d) and western blot (e) analysis of PD-L1 expression in parental, CMTM6-deficient, CMTM6-overexpressing and CMTM6-reconstituted A375 melanoma cells. f, Relative PD-L1 cell surface expression in control or independent CMTM6-knockdown (shCMTM6-4, shCMTM6-6) 8505C thyroid cancer cells with or without IFNγ exposure. g, Western blot analysis of CMTM6 and PD-L1 expression in control or independent CMTM6-knockdown 8505C thyroid cancer cells with or without IFNγ exposure. h, Flow cytometry analysis of PD-L1 expression in control or independent CMTM6-knockdown primary bone marrow progenitor-derived dendritic cells with or without LPS exposure. i, Knockdown efficiency of CMTM6 in primary bone marrow progenitorderived dendritic cells. Data are representative of at least three (a-g) or two (h, i) independent experiments and were analysed by unpaired t-test (b, f). Data represent mean ± s.d. of triplicates (b, d, f, i). ***P < 0.001. MFI, median fluorescence intensity.
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enhanced when CMTM4 was simultaneously targeted ( Fig. 3b and Extended Data Fig. 4a ). More directly, ectopic expression of CMTM4 could fully restore IFNγ-induced PD-L1 expression in CMTM6knockout cells (Extended Data Fig. 4b , c). To understand whether regulation of PD-L1 expression is a specific property of CMTM6 and CMTM4, we individually introduced Flag-tagged versions of all CMTM family members into CMTM6-deficient A375 cells. In contrast to what was observed upon CMTM6 and CMTM4 introduction, expression of other CMTM members (detected for CMTM1, CMTM3, CMTM5 and CMTM7; Extended Data Fig. 4d , e) did not induce a substantial increase in PD-L1 expression, as assessed by either flow cytometry or western blot analysis ( Fig. 3c, d ).
To study the mechanism by which CMTM6 regulates PD-L1 levels, we first assessed the relationship between CMTM6 expression and PD-L1 mRNA levels. Comparison of PD-L1 mRNA levels and cell-surface protein levels at different time points after IFNγ stimulation revealed that whereas CMTM6 depletion greatly reduced PD-L1 cell-surface levels, induction of PD-L1 mRNA by IFNγ was not substantially altered (Fig. 4a, b and Extended Data Fig. 5d ). Notably, both in cell lines (Extended Data Fig. 5a ) and in primary dendritic cells (Extended Data Fig. 5b , c), levels of MHC-I and PD-L2 protein were not significantly affected by CMTM6 inhibition, indicating that although CMTM6 regulates PD-L1 at the protein level, it is not a general regulator of protein translation or stability.
To determine where in the PD-L1 protein life cycle CMTM6 exerts its effect, CMTM6-deficient and CMTM6-overexpressing A375 cells were transduced with a V5-tagged PD-L1 gene. Immunoprecipitation of PD-L1-V5 at different time points after a 1-h 35 S pulse labelling demonstrated a much more rapid decay of PD-L1 in the absence of CMTM6 (fraction PD-L1 remaining at t = 6 h; 94% versus 8%; Fig. 4c and Extended Data Fig. 5e ). Notably, acquisition of PD-L1 resistance to deglycosylation by endoglycosidase H, was equally efficient in both cell populations, indicating that CMTM6 influences PD-L1 protein fate after egress from the endoplasmic reticulum (Extended Data Fig. 5f ).
To reveal the cellular localization of endogenous CMTM6, we performed mass spectrometry analysis of different subcellular fractions, demonstrating that endogenous CMTM6 is predominantly present within the plasma membrane fraction (Extended Data Fig. 6a ) Immunohistochemical analysis confirmed the presence of CMTM6 at the cell membrane (Extended Data Fig. 6b ). Furthermore, immunohistochemical analysis of nine melanomas revealed CMTM6 protein expression in human tumours, and also showed that PD-L1 staining in eight of these samples was restricted to areas with clear CMTM6 expression (Extended Data Fig. 6c ). Similarly, in three out of five PD-L1 + lung cancer samples, we observed PD-L1 localization in CMTM6 + areas.
A hypothesis arising from the above data is that CMTM6 and PD-L1 could interact molecularly. To test this, we performed immunoprecipitation of PD-L1 followed by western blot analysis of CMTM6, and vice versa. In lysates from A375 cells or 8505C cells, anti-PD-L1 antibody co-immunoprecipitated CMTM6. Likewise, PD-L1 was present in anti-CMTM6 immunoprecipitates. As expected, co-immunoprecipitation of PD-L1 and CMTM6 in A375 was dependent upon PD-L1 induction by IFNγ. As a further control for antibody specificity, co-immunoprecipitation of both CMTM6 and PD-L1 was abrogated upon gene inactivation of the partner molecule ( Fig. 4d and Extended Data Fig. 7a, b ). Co-immunoprecipitation was likewise observed for PD-L1 and CMTM4, and CMTM4 and CMTM6 (Extended Data Fig. 7c, d ).
To understand how CMTM6 influences PD-L1 degradation, wildtype, CMTM6-knockout, and CMTM6-overexpressing A375 were transduced with a V5-tagged PD-L1 gene and ubiquitination of PD-L1 was analysed. In the absence of CMTM6, the amount of ubiquitinated PD-L1 was increased, despite the overall lower PD-L1 levels ( Fig. 4e and Extended Data Fig. 8a ), suggesting that CMTM4/6 may protect PD-L1 from ubiquitination. Intriguingly, STUB1, an E3 ubiquitin ligase that has, among others, been implicated in the degradation of Foxp3 in regulatory T cells 24 , was identified as a negative regulator of PD-L1 expression in both haploid genetic screens (Extended Data Fig. 8b , c). To assess whether STUB1 affects PD-L1 degradation, we disrupted STUB1 in either CMTM6-proficient or -deficient A375 cells. Deletion of STUB1 resulted in a stronger increase in PD-L1 levels in CMTM6-deficient than in CMTM6-proficient cells, identifying STUB1 as an E3 ligase that causes destabilization of PD-L1 ( Fig. 4f , g), either directly, by modification of lysines in the PD-L1 cytoplasmic domain, or indirectly. Consistent with the model that CMTM6 may protect PD-L1 by preventing ubiquitination, cellsurface levels of PD-L1-PD-L2 fusion proteins are only influenced by CMTM6 when carrying the PD-L1 transmembrane and intracellular domain (Extended Data Fig. 8d, e ). Exploiting the fact that CMTM6 and PD-L2 do not show detectable association (Extended Data Fig. 8f ), we also used PD-L1-PD-L2 fusion proteins to demonstrate that the PD-L1 transmembrane domain is required for efficient interaction (Extended Data Fig. 8g ). In line with the role of the PD-L1 transmembrane and intracellular domain in CMTM6-mediated stabilization, orientation mapping of CMTM6 revealed that a large part of the molecule is located within the cytosol and cell membrane (Extended Data Fig. 9 ). In view of the broad RNA expression pattern of CMTM6, we assessed the effects of CMTM6 on the membrane proteome in an unbiased manner. Mass spectrometric analysis of a series of independent CMTM6-deficient and -proficient clones revealed that, both within the 8505C thyroid cancer cell line and the RKO colorectal cancer cell line, PD-L1 was the most significantly influenced hit (Fig. 4h , i and Extended Data Fig. 10a, b ). Expression of PD-L1 affects T-cell responsiveness in a quantitative manner, with higher levels of PD-L1 expression leading to an increased impairment of T-cell survival and/or activity 11, 25 . To determine whether CMTM6 influences PD-L1mediated T-cell suppression, we incubated mixtures of MART-I T-cell receptor (TCR)-transduced T cells that expressed different levels of PD-1 with antigen-loaded CMTM6-deficient or -proficient 8505C or A375 cells. IL-2 production of PD-1 int and PD-1 high T cells upon encounter of CMTM6-proficient tumour cells was reduced relative to that of PD-1 − T cells. However, upon CMTM6 disruption in 8505C or A375 tumour cells, IL-2 production of PD-1-expressing T cells was significantly restored ( Fig. 4j and Extended Data Fig. 10c-e ). P a r e n t a l P a r e n t a l P a r e n t a l P a r e n t a l P a r e n t a l 1.6× *** 2.8× *** 2.8× *** Letter reSeArCH
Recent work has revealed a number of mechanisms of transcriptional and post-transcriptional (dys)regulation of the PD-L1 gene in tumour cells [10] [11] [12] [13] [14] [15] . Here we identify CMTM6 and CMTM4 as regulators of PD-L1 protein stability. On the basis of the available data we conclude that CMTM6/4, the two most closely related members of the CMTM family (Extended Data Fig. 4f ), influence PD-L1 expression across a range of cell types. Furthermore, the observations that (i) CMTM6 affects PD-L1 protein stability at late time points after biosynthesis; (ii) CMTM6, CMTM4 and PD-L1 interact, as shown by co-immunoprecipitation; and that (iii) CMTM6 is largely located at the cell surface, collectively suggest a model in which CMTM6 interacts with PD-L1 at the tumour cell surface and thereby protects it from degradation. In line with this model, CMTM6 influences the levels of PD-L1 ubiquitination and absence of the STUB1 E3 ubiquitin ligase partially reverts the CMTM6-knockout phenotype. Intriguingly, for one of the other CMTM family members, CMTM7, cell surface expression has been described in association with the B-cell receptor (BCR) complex, where it may contribute to BCR signalling 26 . It could be speculated that CMTM6 may also fulfil a similar role in the immunological synapse between T cells and tumour cells or antigenpresenting cells. Finally, the co-localization of PD-L1 and CMTM6 in human tumours and the observation that CMTM6 depletion ameliorates PD-L1-mediated T-cell suppression suggest a potential value of CMTM6/4 as therapeutic targets, either in isolation, or to enhance the effectiveness of the current PD-L1-PD-1 blocking therapies.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
MethODS Data reporting. No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. Cell lines. A375, DLD1, RKO, H2030 and H2122 cells were purchased from the American Type Culture Collection (ATCC). 8505C was purchased from the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ). WM2664 and COLO679 cells were gifts from R. Bernards (The Netherlands Cancer Institute). Short-term cell lines from patient-derived melanoma xenografts were generated as described 28 and were a gift from D. Peeper and K. Kemper. HAP1 cells have been described previously 19 . HAP1 cells were cultured in IMDM (Thermo Fisher Scientific) supplemented with 10% fetal calf serum (FCS, Sigma-Aldrich), 100 U ml −1 penicillin-streptomycin (Thermo Fisher Scientific) and l-glutamine (Thermo Fisher Scientific); A375 and short-term melanoma xenograft cultures were maintained in DMEM supplemented with 10% FCS (Sigma-Aldrich) and 100 U ml −1 penicillin-streptomycin (Thermo Fisher Scientific). All other cell lines were cultured in RPMI supplemented with 10% FCS (Sigma-Aldrich) and 100 U ml −1 penicillin-streptomycin (Thermo Fisher Scientific). IFNγ treatment was performed over a period of 48 h at a concentration of 25 ng ml −1 , unless indicated otherwise. Identification of genetic regulators. The approach described in ref. 20 was followed to identify regulators of PD-L1 abundance. Mutagenized HAP1 libraries (starting with either wild-type cells or CMTM6-deficient HAP1 cells) were expanded to approximately 1.5 × 10 9 cells and subsequently treated with 0.5 ng ml −1 IFNγ (Peprotech) for 24 h to induce expression of PD-L1. Subsequently, approximately 3 × 10 9 cells were dissociated using trypsin-EDTA (Life Technologies), washed with PBS and stained with FITC-labelled anti-PD-L1 antibody (BD Pharmingen) at 1:20 dilution for 30 min at room temperature in PBS containing 0.5% w/v bovine serum albumin (Sigma-Aldrich) and 0.2% w/v sodium azide (Sigma-Aldrich). Subsequently, cells were washed three times with PBS containing 1% FCS and stained with FITC-labelled polyclonal goat anti-mouse Ig (BD pharmingen) at 1:100 dilution for 30 min at room temperature in PBS containing 0.5% w/v bovine serum albumin (Sigma-Aldrich) and 0.2% w/v sodium azide (Sigma-Aldrich) to allow signal amplification. Following two washes with PBS containing 1% FCS and one wash with PBS, stained cells were passed through a 40-μm strainer (BD FalconTM) and subsequently fixed using BD fix buffer I (BD biosciences) for 10 min at 37 °C, followed by a wash with PBS containing 1% FCS. Subsequently, cells were permeabilized by suspension in cold BD permeabilization buffer (BD Biosciences) while vortexing, and incubated on ice for 30 min before incubation with 100 μg ml −1 RNase A (Qiagen) and 10 μg ml −1 propidium iodide (Cayman Chemical) at 37 °C temperature for 30 min. Alternatively, cells were subjected to treatment with 3 μM 4′,6-diamidino-2-phenylindole (DAPI) for 30 min. Staining of the cells finished with a final wash in PBS containing 10% FCS. Following staining, cells were sorted on a Biorad S3 Cell sorter (Biorad) or a Moflo Asterios cell sorter (Beckman Coulter) to collect the 1-5% of cells with the highest and lowest PD-L1 staining intensity and 1n DNA content. Sorted cells were used for isolation of genomic DNA and retroviral gene-trap insertion sites were retrieved, mapped and analysed as described in ref. 20 . For PD-L1, it has been described that alterations of the 3′ portion of the gene can stabilize the gene product and lead to higher PD-L1 proteins levels 11 . As this was also recapitulated by our gene-trap insertion method (gene-trap integrations into the 3′ portion of the gene resulted in increased rather than decreased staining intensity for PD-L1), integrations in the portion of the gene downstream of exon 5 (Refseq identifier NM_014143.3) were disregarded where indicated. Generation of knockout cell lines. Knockout cell lines were generated using the CRISPR-Cas9 system. To generate knockout HAP1 cells, cells were transfected with a px330 vector (Addgene 42230) encoding a sgRNA for the gene of interest and a vector encoding a sgRNA for the zebrafish TIA gene (5′-GGTATGTCGGGAACCTCTCC-3′), as well as a P2A-blasticidin-resistance cassette flanked by two TIA target sites. This allows incorporation of the blasticidin-resistance gene into the locus of interest, resulting in a stable knockout, essentially as described 29 . Following blasticidin selection (10 μg ml −1 ), resistant clones were expanded.
To generate knockout A375 and 8505C cells, cells were transfected with pLentiCRISPR v.2 vector (Addgene 52961) encoding sgRNAs targeting nonoverlapping regions of the CMTM6 gene 30 . Following puromycin selection (2 μg ml −1 , for two days), single-cell clones were expanded and gene disruptions were validated by sequencing and western blot analysis.
The sgRNA sequence CCGGGTCCTCCTCCGTAGTG was used to generate the A375 CMTM6-knockout clone CMTM6 KO6, the 8505C CMTM6-knockout clone CMTM6 KO1 and the RKO CMTM6-knockout clone, the sgRNA sequence TCACAATGTACTTTATGTGG was used to generate the A375 CMTM6-knockout clone CMTM6 KO12 and the 8505C CMTM6-knockout clone CMTM6 KO3. The sgRNA sequence ACTGCTTGTCCAGATGACTT was used to generate the A375 PD-L1-knockout clone and the sgRNA sequence GGAGATGGAGAGCTATGATG was used to generate all the STUB1-knockout clones. Immunoprecipitation, SDS-PAGE and western blot analysis. Cells for western blot analysis were seeded in six-well plates and cultured as described in the figure legends. To collect cell lysates, cells were washed with PBS and lysed with RIPA buffer supplemented with freshly added protease inhibitor cocktail (Roche). After incubation on ice for 30 min, cell lysates were centrifuged at 20,000g for 15 min at 4 °C. Supernatants were subsequently processed using a Novex NuPAGE Gel Electrophoresis System, according to the manufacturer's instructions (Thermo Fisher Scientific).
Cells for (co)immunoprecipitation experiments were seeded in 15-cm dishes and cultured as described in the figure legends, using 5 million cells per immunoprecipitation reaction. Cells were washed with cold PBS buffer and lysed in CHAPS buffer (1% CHAPS, 50 mM Tris-HCl pH 7.5, 150 mM NaCl). For the detection of protein ubiquitination, cells were lysed in denaturing buffer (50 mM Tris-HCl, 0.5 mM EDTA and 1% SDS) followed by heating at 95 °C for 10 min and then quenched by adding nine volumes of quenching buffer (0.5% Triton X-100, 20 mM Tris-HCl (pH 8.0), 137 mM NaCl, 10% glycerol, 2 mM EDTA). Protease inhibitor cocktail (Roche) was freshly added to all buffers. Cell lysates were incubated on a rotator for 30 min at 4 °C, and then centrifuged at 20,000 g for 15 min at 4 °C. Supernatants were subsequently processed using Dynabeads Protein A or Protein G for Immunoprecipitation (Thermo Fisher Scientific), and the indicated antibodies. The final elute was processed and western blot analysis was performed using a Novex NuPAGE Gel Electrophoresis System, according to the manufacturer's instructions (Thermo Fisher Scientific). Pulse-chase and EndoH or PNGaseF treatment. V5-tagged PD-L1-transduced CMTM6-overexpressing A375 cells and V5-tagged PD-L1-transduced CMTM6knockout A375 cells were cultured in methionine-and cysteine-free medium for 1 h at 37 °C. Cells were then pulse labelled with 0.5 mCi ml Immunoprecipitates were run on NuPAGE 4-12% gels. Gels were treated with 1 M Na salicylate pH 5.6 before drying, and then analysed on Fujifilm BAS-MP phosphor imager screens. Quantification was performed using a Fujifilm FLA-3000 phosphor imager and AIDA image analyser software. Gels were exposed to film using intensifier screens at −80 °C. Viral vectors. Lentiviral shRNA vectors were retrieved from the arrayed TRC human genome-wide shRNA collection. Additional information is available at http://www.broadinstitute.org/rnai/public/clone/search using the TRCN number. The following lentiviral shRNA vectors were used: shCMTM6-4: TRCN0000127888; shCMTM6-6: TRCN0000130177; shCMTM4-1: TRCN0000142717; shCMTM4-2: TRCN0000142470. PD-L1, PD-1, PD-L2, CMTM6, CMTM4 and PD-L1-PD-L2 chimaeras expressing lentiviral vectors were generating by insertion of the relevant gBlock (IDT) into a pCDH-CMV-MCS-EF1-Puro (CD510B-1, System Bioscience)-derived vector in which the puromycin-resistance cassette was substituted with a blasticidin-resistance cassette. PD-L1-PD-L2 chimaeras were generated as follows. Each section in brackets is a separate unit of amino acids (a.a.) from PD-L1 or PD-L2 or the sequence of the V5-tagged PD-L1 was retrieved from the CCSB-Broad Lentiviral Expression Library (ccsbBroad304_15876). CMTM family members were ordered as individual gBlocks (IDT) coding for the different family members using Ensembl gold transcripts ENST00000379500.6 (CMTM1), ENST00000268595.2 (CMTM2), ENST00000361909.8 (CMTM3), ENST00000330687.8 (CMTM4), ENST00000339180.8 (CMTM5), ENST00000205636.3 (CMTM6), ENST00000334983.9 (CMTM7), ENST00000307526.3 (CMTM8) C-terminally fused with a Flag tag, preceded by a short AAV-linker and cloned into the pMX-IRES-Blast vector using restriction enzymes BglII and SalI (CMTM1 and Letter reSeArCH CMTM4), EcoRI and NotI (CMTM2) or BamHI and SalI (CMTM3, CMTM5, CMTM6, CMTM7 and CMTM8). The retroviral vector pBABE-Puro encoding C-terminally Flag-tagged CMTM6 (pBp-CMTM6-Flag) was generated by cloning a gBlock for CMTM6 (ENST00000205636.3) digested with BamHI and XhoI into pBABE-Puro digested with BamHI and SalI.
For production of lentiviral particles, the described plasmids were co-transfected into HEK293T cells along with packaging plasmids (pPAX2, pVSV-G). Two days after transfection, lentiviral supernatant was collected and used for transduction. Retroviral particles were produced and purified as described for HAP1 mutagenesis, except that multiple collections and ultracentrifugation were omitted. Two days after transduction, cells were selected by exposing them to blasticidin or puromycin. Antibodies. The following antibodies were used for western blot analyses and immunoprecipitation: anti-HSP90: H114 (SantaCruz); anti-CMTM6: HPA026980 (Atlas) or anti-CMTM6 monoclonal antibody (clone RCT8) directed against a peptide in the C-terminal domain of CMTM6 generated by Absea; anti-CMTM4: HPA014704 (Atlas); anti-PD-L1 for western blot analysis: 405.9A11 (Cell Signaling) or immunoprecipitation: E1L3N (Cell Signaling); normal rabbit IgG: 2729 (Cell Signaling); anti-Flag tag: M2 (Sigma-Aldrich); anti-V5 tag: R960-25 (Thermo Fisher Scientific); anti-STUB1 sc133066 (Santa Cruz); anti-ubiquitin antibody: 3933 (Cell Signaling); goat anti-mouse IgG (H + L)-HRP conjugate (BIO-RAD); and goat anti-rabbit IgG (H + L)-HRP conjugate (BIO-RAD). The following antibodies were used for flow cytometry: anti-PD-L1: M1H1 (eBioscience); anti-PD-L2: 24F.10C12 (Biolegend); anti-MHC-I: BB7.2 (BD bioscience); anti-mouse TCRβ: H57-597 (BD Bioscience); anti-CD8: RPA-T8 (BD bioscience); anti-CD3: SK7 (eBioscience); anti-PD-1: eBioJ105 (eBioscience); anti-IL-2: 554567 (BD Bioscience). The following antibodies were used for immuno histochemistry: anti-PD-L1: 22C3 (DAKO); the anti-CMTM6 monoclonal antibody (clone RCT6) directed against a peptide in the C-terminal domain of CMTM6 was generated by Absea. RNA isolation, first strand cDNA synthesis and RT-qPCR. Total RNA was isolated from cells using the RNeasy Mini Kit (Qiagen). cDNA was obtained by reverse transcription using the Maxima First Strand cDNA Synthesis Kit for RT-qPCR (Thermo Fisher Scientific), according to the manufacturer's instructions. SensiFAST SYBR No-ROX Kit (Bioline) was used for RT-PCR gene expression analysis, carried out on Roche LightCycler 480 platform. Relative mRNA levels were normalized to GAPDH mRNA levels. Primer sets used were as follows: CD274-F: ATTTGGAGGATGTGCCAGAG; CD274-R: CCAGCACACTGAGAATCAACA; GAPDH-F: AAGGTGAAGGTCGGAGTCAA; GAPDH-R: AATGAAGGGG TCATTGATGG. IL-2 production assay. Human peripheral blood T cells (Sanquin) were activated and transduced with a retroviral vector encoding the MART-I specific 1D3 TCR as described 31 and with a lentiviral vector encoding PD-1. MART-I TCR and PD-1 expression was validated by flow cytometry. Both 8505C (parental and CMTM6-KO) and A375 cells (parental, PD-L1-overexpressing, and CMTM6-KO PD-L1-overexpressing) were pulsed with 10 ng ml −1 MART-I(26-35) peptide for 1 h at 37 °C. Next, 1 × 10 5 transduced T cells were incubated with 1 × 10 5 peptide-pulsed tumour cells or non-pulsed tumour cells in the presence of 1 μl ml −1 Golgiplug (BD Biosciences). After a 5-h incubation at 37 °C, cells were washed and stained with phycoerythrin (PE)-labelled anti-mouse TCRβ chain, V500-labelled anti-CD8, PerCP Cy5.5-labelled anti-CD3 and PE Cy7-labelled anti-PD-1 and analysed for IL-2 production by intracellular cytokine staining. Activity of T cells with different levels of PD-1 expression was analysed by gating on mouse TCRβ-chain-positive cells expressing low, intermediate or high levels of PD-1. Membrane fractionation and MS analysis. Snap-frozen cell pellets were lysed by gentle homogenization in isotonic buffers supplemented with phosphatase inhibitor (PhosSTOP, Roche) and protease inhibitor (cOmplete mini EDTA-free, Roche). Cellular disruption of >95% was confirmed by microscopy. Plasma membrane (F4), inner membrane (F3) and cytosolic (F1) fractions were prepared by differential centrifugation using a plasma membrane purification kit (Abcam, ab65400).
From fractions F1, F3 and F4, 20 μg of protein was diluted 20 times in 50 mM ammonium bicarbonate, reduced in 4 mM dithiothreitol (DTT), alkylated in 8 mM iodoacetamide (IAA) and digested sequentially at 37 °C with 1:75 Lys C (Wako) and 1:50 trypsin (Sigma-Aldrich) for 4 and 12 h, respectively. Digested peptides were acidified to 0.1% formic acid (FA) and purified by strong cation exchange (SCX) STAGE tips, using as loading buffer: 80% acetonitrile (ACN), 0.1% FA and as elution buffer: 0.5 M ammonium acetate, 20% ACN, 0.1% FA. Eluted peptides were dried by vacuum and 4 μg equivalent of peptides was analysed in a 3 h reversephase separation on the UHPLC 1290 system (Agilent) coupled to an Orbitrap Q Exactive HF mass spectrometer (Thermo Fisher Scientific). SCX flowthrough from cytosolic fraction (denoted F2) was analysed separately to increase proteome coverage. RP-nanoLC-MS/MS. Proteomics data were acquired using an UHPLC 1290 system (Agilent) coupled to an Orbitrap Q Exactive HF spectrometer (Thermo Scientific). Peptides were first trapped on a 2 cm × 100 μm Reprosil C18 precolumn (3 μm) and then separated on a 50 cm × 75 μm Poroshell EC-C18 analytical column (2.7 μm). Trapping was performed for 10 min in 0.1 M acetic acid (solvent A) and elution with 80% ACN in 0.1 M acetic acid (solvent B) in gradients as follows: 10-40% solvent B in 155 min, 40-100% in 3 min and finally 100% for 1 min. Flow was passively split to 300 nl min −1 . MS data were obtained in datadependent acquisition mode. Full scans were acquired in the m/z range of 375-1,600 at the resolution of 35,000 (m/z 400) with AGC target 3 × 10 6 . The top 15 most intense precursor ions were selected for HCD fragmentation performed at normalized collision energy (NCE) 25%, after accumulation to target value of 5 × 10 4 . MS/MS acquisition was performed at a resolution of 17,500. Database search. Raw files were processed using MaxQuant version 1.5.3.30 and searched against the human Swissprot database (version May 2016) using Andromeda.
Cysteine carbamidomethylation was set to fixed modification, while variable modifications of methionine oxidation and protein N-terminal acetylation, as well as up to 2 missed cleavages were allowed. The false discovery rate (FDR) was restricted to 1% in both protein and peptide identification. Label-free quantification (LFQ) was performed with 'match between runs' enabled. Analysis of CMTM6 RNA levels and correlation between CMTM6 and CD274 RNA levels in TCGA samples. TCGA RNA sequencing data were downloaded from the Broad TCGA genome data analysis centre 1 November 2015 release of the standard runs (http://gdac.broadinstitute.org/runs/stddata). For projects where data from multiple sequencing platforms were available, Illumina HiSeq data was preferentially used. The (RSEM) normalized read count field was multiplied by 10 6 to arrive at the reported TPM expression values. Correlation coefficients and associated unadjusted P values between CMTM6 and CD274 were computed per TCGA-sequencing project with Pearson's method. Two-dimensional kernel density estimates were computed using the MASS::kde2d() function in version 3.3.1 of the R programming language. We computed the correlations between CMTM6 and 10 4 randomly selected genes (identical between sequencing projects) to obtain a reference distribution of correlation coefficients for CMTM6, specific for each TCGA project. The reported empirical P values are defined as one minus the quantile of the CMTM6 and CD274 correlation within this reference distribution. Immunohistochemistry. Immunohistochemistry of the formalin-fixed paraffin-embedded samples was performed on a BenchMark Ultra autostainer (Ventana Medical Systems). In brief, 3 μm paraffin serial sections were cut, heated at 75 °C for 28 min and deparaffinized in the instrument with EZ prep solution (Ventana Medical Systems). Heat-induced antigen retrieval was carried out using Cell Conditioning 1 (CC1, Ventana Medical Systems) for 48 min for PD-L1 and 64 min for CMTM6 antibodies at 95 °C.
PD-L1 clone 22C3 (DAKO) was used at 1:40 dilution, 1 h at room temperature and CMTM6 clone RCT6 was used directly from hybridoma supernatant at either 1:500 or 1:1,000 dilution for tumour samples and 1:100 dilution for cell lines, 1 h at room temperature. Bound antibody was detected using the OptiView DAB Detection Kit (Ventana Medical Systems). Slides were counterstained with Haematoxylin and Bluing Reagent (Ventana Medical Systems).
Patient melanoma samples were obtained (following Institutional Review Board approval) from the NKI-AVL pathology archive biobank and selected for PD-L1 expression. Statistical analysis. All student t-tests were two-tailed under the assumption of equal variance between samples. Data availability. All sequencing datasets have been deposited in the NCBI Sequence Read Archive under accession number SRP108407. In addition, all processed screen results are accessible in an interactive database (https://phenosaurus. nki.nl/). Source Data for the main and extended data figures are provided in the online version of the paper. Note the bias towards integrations within introns 5 and 6 in the PD-L1 gene in PD-L1 high cells relative to PD-L1 low cells, consistent with the structural variants beyond exon 4 of PD-L1 that have been shown to result in increased PD-L1 expression in a subset of adult T-cell leukaemia, diffuse large B-cell lymphoma and stomach cancers 11 . c, Screen data as depicted in Fig. 1, but CESC r = 0.48 (p = 3.09 × 10 −3 )
Empirical p = 0.142 DLBC r = 0.14 (p = 5.97 × 10 −2 )
Empirical p = 0.494 ESCA r = 0.36 (p = 2.56 × 10 −6 )
Empirical p = 5.87 × 10 −2 KIRC r = 0.37 (p = 1.01 × 10 −10 )
Empirical p = 0.341 LGG r = 0.41 (p = 3.54 × 10 −16 )
Empirical p = 0.177 LUAD r = 0.18 (p = 6.7 × 10 −5 )
Empirical p = 0.203 STAD r = 0.22 (p = 6.5 × 10 −3 )
Empirical p = 0.443 TGCT r = 0.38 (p = 1.64 × 10 −18 )
Empirical p = 0.289 THCA r = 0.33 (p = 9.47 × 10 −6 )
Empirical p = 0.287 Because randomly selected genes are on average also weakly positively correlated (not shown), empirical P values, which represent one minus the quantile of the CMTM6-and CD274-expression correlation coefficient among a reference distribution composed of correlation coefficients between CMTM6 and randomly selected genes, are also depicted.
Empirical P values smaller than 0.5 denote a stronger correlation between CMTM6 and CD274 than the median observed correlation in the reference distribution. , h) , RKO colorectal cancer cells (i, j) and H2030 non-smallcell lung cancer cells (l, m). k, n, Western blot analysis of CMTM6 and PD-L1 expression in RKO colorectal cancer cells (k) and H2030 non-small cell lung cancer cells (n). Cells are independently transduced with two vectors expressing different CMTM6 shRNAs and are compared with cells transduced with the control vector. In all cases, cells treated with IFNγ (25 ng ml −1 ) or left untreated were compared. g, The graph shown is identical to Fig. 2f , shown again here to facilitate comparison. Data are representative of three (c-n) , two (a, b, o, p) or one (q) independent experiments and were analysed by unpaired t-test (a, c, e, g-m, o, q) .
Data are mean ± s. d. of triplicates (a, c, e, g-m, o, q) . ***P < 0.001. Ctrl, control; MFI, median fluorescence intensity. CRC, colorectal cancer; NSCLC, non-small-cell lung cancer; PDX, patient-derived xenograft. Extended Data Figure 6 | Specificity and membrane localization of CMTM6, and co-localization with PD-L1 in human tumours. a, Membrane-fractionated proteome of 8505C and RKO cells. CMTM6 and PD-L1 were detected by LC-MS/MS predominantly from the plasma membrane fractions. Label-free quantification (LFQ) performed by intensity-based normalization of four fractions together across different cell lines is depicted. b, A375 parental cells, CMTM6-knockout or CMTM6-overexpressing cells were fixed and formalin embedded, and stained for CMTM6 with a monoclonal antibody (clone RCT6) generated against a peptide from the C-terminal domain of CMTM6. Analysis shows a mainly membranous stain, as indicated by the arrowheads. c, Sequential slides from lymph node and subcutaneous metastases from three melanoma patients were stained for PD-L1 (left) or CMTM6 (right), showing frequent localization of PD-L1 within CMTM6 + areas. In total, samples from nine melanoma patients and five PD-L1 + lung cancer samples were analysed. KO, knockout; OE, overexpression.
Extended Data Figure 7 | Interactions between CMTM6, PD-L1 and CMTM4, and effect of CMTM6 on PD-L1 stability. a, A375 parental cells, CMTM6-deficient cells, PD-L1-deficient cells and cells ectopically expressing CMTM6 or PD-L1, were cultured in the absence or presence of 25 ng ml −1 IFNγ for 48 h before preparation of cell lysates. Immunoprecipitation was performed using a CMTM6-specific antibody immobilized on protein-A-coated beads. Immunoprecipitates and whole cell lysate were subjected to SDS-PAGE and immunoblotted for CMTM6 and PD-L1. Two exposures of the same western blot are shown. Arrows indicate PD-L1 bands. b, Parental and CMTM6-deficient 8505C cells were cultured in the absence or presence of 50 ng ml −1 IFNγ for 72 h before preparation of cell lysates. Immunoprecipitation was performed using CMTM6-or PD-L1-specific antibodies immobilized on protein-A-coated beads. Immunoprecipitates and whole cell lysates were subjected to SDS-PAGE and immunoblotted for CMTM6 and PD-L1. Two exposures of the same western blot are shown. Normal IgG served as a control. Arrows indicate PD-L1 bands. c, d, Parental and CMTM6-knockout RKO cells (c) and 8505C cells (d) were lysed and immunoprecipitation was performed using antibodies immobilized on protein-G-coated beads as indicated. Immunoprecipitates and whole-cell lysates were subjected to SDS-PAGE, and western blot analysis of CMTM4 and PD-L1 expession was carried out. Two exposures of the same western blots are shown. Arrows indicate CMTM4 (c) or PD-L1 (d). Data are representative of three independent experiments. KO, knockout; OE, overexpression. 
